How to overcome the 'double-lock' barrier to entry for generic inhalers

In the pharmaceutical industry, a good opportunity is generally one that provides sustainable cash flows, is worth a significant amount of money and provides barriers against competition. The asthma and COPD market is one that meets these criteria and the race is on amongst branded generic (BGx) / generic (Gx) manufacturers to enter the market, which will be worth $24.5bn by 2020 in EU5 and US. In 2014, the leading products Advair (fluticasone+salmeterol) and Symbicort (budesonide+formoterol) generated $5.9bn and $2.9bn respectively. These products have sustained commercial success despite the active molecules being off-patent. The molecule patent for Advair either expired or was revoked in the US and 5EU markets in 2010. For Symbicort, the primary patent in the 5EU expired in 2012 and in the US in 2014.

In the pharmaceutical industry, a good opportunity is generally one that provides sustainable cash flows, is worth a significant amount of money and provides barriers against competition. The asthma and COPD market is one that meets these criteria and the race is on amongst branded generic (BGx) / generic (Gx) manufacturers to enter the market, which will be worth $24.5bn by 2020 in EU5 and US. In 2014, the leading products Advair (fluticasone+salmeterol) and Symbicort (budesonide+formoterol) generated $5.9bn and $2.9bn respectively. These products have sustained commercial success despite the active molecules being off-patent. The molecule patent for Advair either expired or was revoked in the US and 5EU markets in 2010. For Symbicort, the primary patent in the 5EU expired in 2012 and in the US in 2014.

Setting the scene

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Respiratory

More from Therapy Areas

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By 

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.